MRK · News · 20260911N

Product / Drug Pipeline Progress

Merck & Co., Inc. · 2026-09-11 · Importance 31 · Surprise 42

Merck is expanding its drug pipeline and newer-product portfolio to offset the expected loss of exclusivity for Keytruda in 2028. Keytruda’s patent expiry represents a major future competitive and demand risk for Merck’s oncology franchise. The reported strategy relies on pipeline growth and new drug launches to support long-term pharmaceutical sales after Keytruda’s exclusivity period ends.

Key facts

• Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 loss of exclusivity (LOE) and drive long-term growth. source
• Merck is banking on a growing pipeline and new drugs to offset Keytruda LOE. source